Background. Although the incidence of adenocarcinomas of the gastroesophageal junction (GEJ) is sharply rising in the Western world, there are still some disagreements about the staging and the treatment of this disease. The aim of this retrospective study was to analyse the effectiveness and safety of postoperative radiochemotherapy in patients with a GEJ adenocarcinoma treated at the Institute of Oncology Ljubljana.
Patients and methods. Seventy patients with GEJ adenocarcinoma, who were treated with postoperative radiochemotherapy between January 2005 and June 2010, were included in the study. The treatment consisted of 6 cycles of chemotherapy with 5-FU and cisplatin and concomitant radiotherapy with the total dose of 45 Gy.
Results. Twenty-six patients (37.1%) completed the treatment according to the protocol. The median follow-up time was 17.7 months (range: 3.3-64 months). Acute toxicity grade 3 or more, such as stomatitis, dysphagia, nausea or vomiting, and infection, occurred in 2.9%, 34.3%, 38.6% and 41.5% of patients, respectively. At 3 years locoregional control (LRC), disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) were 78.2%, 25.3%, 35.8%, and 33.9%, respectively. In the multivariate analysis of survival, splenectomy and level of Ca 19-9 >20 kU/L before the adjuvant treatment were identified as independent prognostic factors for lower DFS, DSS and OS. Age <60 years, higher number of involved lymph nodes and advanced disease stage were identified as independent prognostic factors for lower DSS and OS.
Conclusions. In patients with GEJ adenocarcinoma who first underwent surgery, postoperative radiochemotherapy is feasible, but we must be aware of a high risk of acute toxic side effects.
1. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85: 1457-9.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistic, 2002. CA cancer J Clin 2005; 55: 74-108.
3. American Joint Committee on Cancer. AJCC cancer staging manual, 7th edition. New York: Springer-Verlag; 2009.
4. Wronski M, Ziarkiewicz-Wroblewska B, Slodkowski M, Cebulski W, Gornicka B Krasnodebski IW. Mesenteric fibromatosis with intestinal involvement mimicking a gastrointestinal stromal tumour. Radiol Oncol 2011; 45: 59-63.
5. Oblak I, Velenik V, Anderluh F, Strojan P. Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia. Eur J Surg Oncol 2007; 33: 982-7.
6. Oblak I, Anderluh Franc, Velenik V. Postoperative radiochemotherapy for gastric adenocarcinoma: long term results. Radiol Oncol 2009; 43: 274-81.
7. Power DG, Reynolds JV. Localized adenocarcinoma of the esophagogastric junction-is there a standard of care? Cancer Treatm Rev 2010; 36: 400-9.
8. Wayman J, Bennet MK, Rames SA, Griffin SM. The pattern of recurrence of adenocarcinoma of the oesophagogastric junction. Br J Cancer 2002; 86: 1223-9.
9. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-8.
10. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-7.
11. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-92.
12. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-53.
13. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann G, et al.. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30.
14. Kim S, Lim DH, Lee J, Kang WK, MacDonald S, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Bio Phys 2005; 63: 1279-85.
15. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 335: 11-20.
16. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-21.
17. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-6.
18. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-34.
19. Fok M, Sham JS, Choy D, Cheng SW, Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993; 173: 138-47.
20. Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French university association for surgical research. Surg Gynecol Obstet 1991; 173: 123-30.
21. Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 2009; 96: 23-33.
22. Liu TS, Wang Y, Chen SY, Sun YH. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008; 34: 1208-16.
23. Ajani JA, Welch SR, Raber MN, Fiels WS, Krakoff IM. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-59.
24. ICRU 50: Prescribing, recording, and reporting photon beam therapy. Bethesda: International Commission on Radiation Units and Measurements Press; 1993.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
26. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
27. Cox DR. Regression models and life-tables. J R Stat Soc Bull 1972; 34: 187-220.
28. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241-52.
29. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from 18 major cancers in 1985. Int J Cancer 1993; 55: 891-903.
30. Torrente S, Turri L, Deantonio L, Cena T, Gambaro G, Magnani C, et al. Concomitant chemo-radiotherapy for unresectable oesophageal cancer: A mono-institutional study on 40 patients. Rep Pract Oncol Radiother 2012; 17: 226-32.
31. Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GMM, Murthy SC, et al. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol 2009; 4: 1264-9.
32. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 2006; 15: 751-64.
33. Weitz J, Jaques DP, Brennan M, Karpeh M. Association of splenectomy with postoperative complications in patients with proximal gastric and gastroesophageal junction cancer. Ann Surg Oncol 2004; 11: 682-9.
34. Pultrum BB, van Bastelaar J, Schreurs MA, van Dullemen HM, Groen H, Nijsten MWN, et al. Impact of splenectomy on surgical outcome in patients with cancer of the distal esophagus and gastro-esophageal junction. Dis Esophagus 2008; 21: 334-9.
35. Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 2006; 24: 4347-55.
36. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the US. Cancer 2002; 95: 1434-43.
37. Steup WH, de Leyn P, Deneffe G, van Raemdonck D, Coosemans W, Lerut T. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg 1996; 111: 85-94.
38. Mariette C, Taillier G, van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004; 78: 177-83.
39. Lerut T, Coosemans W, Decker G, de Leyn P, Moons J, Nafteux P, et al. Extended surgery for cancer of the esophagus and gastroesophageal junction. J Surg Res 2004; 117: 58-63.
40. Predrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, et al. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg 2007; 134: 378-85.
41. Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1002 consecutive patients. Ann Surg 2000; 232: 353-61.
42. Crumley ABC, Stuart RC, McKernan M, Going JJ, Shearer CJ, McMilan DC. Comparison of the pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system. J Gastrointest Surg 2010; 14: 781-7.
43. Deans DAC, Tan BH, Wigmore SJ, Ross JA, de Beaux AC, Paterson-Brown S, et al. The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br J Cancer 2009; 100: 63-9.
44. Stahl M, Wilke H, Stuschke M, Walz MK, Fink U, Molls M, et al. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 2005; 131: 67-72.
45. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DB, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. . N Engl J Med 1998; 339: 1979-84.
46. Plaisant N, Senesse P, Azria D, Lemanski C, Ychou M, Quenet F, et al. Surgery for esophageal cancer after concomitant radiochemotherapy: oncologic and functional results. World J Surg 2005; 29: 32-8.
47. Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-44.
48. Leigh Y, Seagroatt V, Goldacre M, McCulloch P. Impact of socio-economic deprivation on death rates after surgery for upper gastrointestinal tract cancer. Br J Cancer 2006; 95: 940-3.
49. Sabel MS, Smith JL, Nava HR, Mollen K, Douglass HO, Gibbs JF. Esophageal resection for carcinoma in patients older than 70 years. Ann Surg Oncol 2002; 9: 210-4.
50. McKernan M, McMillan DC, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. Br J Cancer 2008; 98: 888-93.
51. Sauvanet A, Mariette C, Thomas P, Lozac’h P, Segol P, Tiret E, et al. Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors. J Am Coll Surg 2005; 201: 253-62.
52. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-30.
53. Schmid A, Thybusch A, Kremer B, Henne-Bruns D. Differential effects of radical D2-lymphadenectomy and splenectomy in surgically treated gastric cancer patients. Hepatogastroenterology 2000; 47: 579-85.
54. Huang CM, Wang JB, Lu HS, Zheng CH, Li P, Xie JW, et al. Prognostic impact of splenectomy on advanced proximal gastric cancer with more than 10 lymph node metastasis. Chin Med J 2009; 122: 2757-62.
55. Buyukasik O, Hasdemir AO, Gulnerman Y, Col1 C, Ikiz O. Second primary cancers in patients with gastric cancer. Radiol Oncol 2010; 44: 239-43.
56. Ikequchi M, Kaibara N. Lymph node metastasis at the splenic hilum in proximal gastric cancer. Am Surg 2004; 70: 645-8.
57. Kočevar N, Odreman F, Vindigni A, Grazio SF, Komel R. Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers. World J Gastroenterol 2012; 18: 1216-28.